JPMorgan Chase & Co. Has $856.47 Million Stake in IQVIA Holdings Inc. $IQV

JPMorgan Chase & Co. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 16.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,799,600 shares of the medical research company’s stock after buying an additional 528,753 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.23% of IQVIA worth $856,468,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new position in IQVIA in the fourth quarter worth $25,000. International Assets Investment Management LLC acquired a new position in IQVIA in the fourth quarter worth $27,000. Activest Wealth Management boosted its stake in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new position in IQVIA in the third quarter worth $30,000. Finally, Palladiem LLC acquired a new position in IQVIA in the fourth quarter worth $40,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Barclays raised IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday, March 6th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Truist Financial reduced their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Trading Up 1.4%

Shares of IQV opened at $186.27 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The firm has a market capitalization of $31.09 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 1.58 and a beta of 1.21. The stock’s fifty day simple moving average is $172.86 and its 200-day simple moving average is $194.33.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the firm posted $2.70 earnings per share. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its board has approved a share repurchase plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.